QED Therapeutics, an affiliate within BridgeBio Pharma, focuses on developing targeted treatments for FGFR-driven skeletal dysplasia, particularly Achondroplasia. Achondroplasia is the most common form of genetically driven short stature and can cause potentially debilitating medical complications. With our experimental therapeutic candidate, infigratinib, we seek to provide an option for children living with Achondroplasia and their families. Reporting to the Vice President, Quality, the Director/Sr. Director, Vendor Quality Management provides strategic and operational leadership for the qualification, oversight, and performance management of contract manufacturers (CMOs), contract laboratories, suppliers, and service providers supporting GxP activities.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director